QIAGEN logo

Drug Repurposing with HSMD

How biopharmaceutical companies can accelerate indication expansion and repurposing of PIK3CA kinase inhibitors

Repurposing existing cancer drugs can potentially expedite the drug development process, provide patients with quicker access to life-saving treatments, increase survival rates, and reduce side effects. In this case study, learn how biopharmaceutical companies can use the Human Somatic Mutation Database (HSMD) to identify potential new indications for existing cancer therapies.


Download the case study
Thank you for your interest. A sales team member will contact you shortly.

Dummy field DO NOT USE/ DELETE/ MODIFY Needs to be hidden in CSS on LP
Required only for USA & Canada
(Enter a valid phone number, with country code and area code, in this format:+11234567890)
Enter the official name






I hereby give QIAGEN the consent to contact me via email and phone (subject to the contact information provided above) with further contests, special offers and product information.

* Mandatory fields

Subject to your consent given above, QIAGEN may use your personal information for internal business and marketing purposes. The information will not be sold to any third party. QIAGEN may transfer your personal information to our CRM system (hosted by SalesForce.com, Inc. and Oracle Corp.) solely for the purposes of data hosting, phone calls and QIAGEN email distribution. You may unsubscribe at any time. Your data will be processed in compliance with applicable privacy laws including the EU General Data Protection Regulation. All information you provide in this site will be governed by our Privacy Policy.